Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Part of paid clinical trials in Duarte, California.

Sponsor
University of Southern California
Study ID
NCT03858205
Status
Recruiting
Apply to this trial

Conditions

  • Bone Pain
  • Metastatic Malignant Neoplasm in the Bone
  • Plasma Cell Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Questionnaire Administration — OTHER
    Ancillary studies
  • Radiation Therapy — RADIATION
    Receive low-dose radiation therapy

Study Details

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

Key Dates

First listed
Feb 28, 2019
Start date
Mar 11, 2019
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Mar 11, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (low-dose radiation therapy)
    Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the absence of disease progression or unacceptable toxicity. Patients with no pain relief may receive additional radiotherapy at 4 weeks following initial radiotherapy.

Primary Outcome Measure

Pain response [ Time Frame: Up to 6 months after completion of radiation therapy ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Bianca Del Vecchio
[email protected]
626-218-4402
Savita V Dandapani, MD (PRINCIPAL_INVESTIGATOR)
Cedars Sinai Medical CenterLos AngelesCalifornia90048
Chace Henning
[email protected]
310-423-8218
Harpavan Sandha
[email protected]
310-423-4849
Leslie Ballas, MD (PRINCIPAL_INVESTIGATOR)
Los Angeles General Medical CenterLos AngelesCalifornia90033
Donna Fernando, RN
[email protected]
323-409-4388
Adam Garsa, MD (PRINCIPAL_INVESTIGATOR)
USC / Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Donna Fernando, RN
[email protected]
323-409-4388
Adam Garsa, MD (PRINCIPAL_INVESTIGATOR)
Emory University Hospital/Winship Cancer InstituteAtlantaGeorgia30322
Mohammad K. Khan
[email protected]
404-778-3473
Mohammad K. Khan (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02215
Patrick Boyle
[email protected]
617-582-8918
Carol Mayo
[email protected]
508-488-3800
Andrea K. Ng (PRINCIPAL_INVESTIGATOR)
University of Minnesota - Masonic Cancer CenterMinneapolisMinnesota55455
Kate Bak
[email protected]
612-301-0151
Stephanie Terezakis, MD (PRINCIPAL_INVESTIGATOR)
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Richard L. Bakst
[email protected]
212-241-3545
Richard L. Bakst (PRINCIPAL_INVESTIGATOR)
University of Pennsylvania/Abramson Cancer CenterPhiladelphiaPennsylvania19104
Jhohanna Perez
[email protected]
267-299-9643
John Plastaras, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By research site
City of Hope· Duarte, CACedars Sinai Medical Center· Los Angeles, CALos Angeles General Medical Center· Los Angeles, CAUSC / Norris Comprehensive Cancer Center· Los Angeles, CAEmory University Hospital/Winship Cancer Institute· Atlanta, GADana-Farber Cancer Institute· Boston, MA

Related Studies